1 of 1
Story summary
- Regeneron researchers identified a rare loss-of-function FNIP1 mutation present in about one in 7,000 people.
- Among 150 carriers, blood lipids, liver fat and blood sugar were lower, with disease risk about 60 % lower.
- Silencing FNIP1 in liver cells activated fat-burning genes and, in mice on a sugary diet, halted weight gain and fibrosis over 30 weeks.
- Researchers say liver-targeted FNIP1 inhibition could help, but a drug remains years away.
